|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/6/2007 10:15:28 AM
HAYWARD, Calif.--(BUSINESS WIRE)--Sepragen Corporation (Pink Sheets:SPGNA), a provider of patented technology and equipment for bio-processing needs in the biotech industry, today announced that it has completed the acquisition of Cyto Biologic Technologies, Inc. Terms of the acquisition were not disclosed. Of the acquisition, Vinit Saxena, CEO of Sepragen, stated, “The consummation of the acquisition of Cyto Biologic Technologies allows Sepragen to provide our bio-processing customers with an innovative technology to rapidly grow cells to high densities with resultant higher productivity.” Saxena continued, “What is most significant is that this is the first step in transforming Sepragen from being a supplier of individual tools to becoming a value-added solution provider in the bio-processing space. Cells grown on the bioreactor produce biological molecules, which can be further processed by several technologies, including Sepragen columns, resins and QuantaSep systems.”
|
|
|
|
|
|
|
|
|
|
|